- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
UK's NICE Wins Drug Price War With GSK
Although approved last September in the European Union, the National Institute for Health and Care Excellence had refused to cover the drug at the company-dictated price, which resulted in patients paying out-of-pocket.
A skin cancer drug developed by GlaxoSmithKline will be available through the United Kingdom's National Health Service after the company agreed to a secret discount.
Tafinlar, which fights melanoma, has won the green light from the National Institute for Health and Care Excellence (NICE), provided GSK supplies it at an undisclosed discount to the £1,400-per-week list price.
The drug has been approved for use in the European Union since September 2013, but once it has received final NICE approval, patients will not need to pay out of pocket to use it.
NICE said it had fast-tracked its recommendation for Tafinlar to the final draft stage in order to accelerate access to the treatment.
Link to the article: http://bit.ly/1p2mXwy
Source: The Telegraph
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
